Abstract
Histone proteins are subject to a diverse range of post-translational modifications which, along with DNA methylation, play a major role in controlling gene expression, cell division, survival and differentiation. Alterations in these chromatin modifications are thought to contribute to important human diseases including cancer. Inhibition of the enzymes that introduce and remove these chromatin modifications is proving an effective approach to cancer therapy and inhibitors of histone deacetylases and DNA methyltransferases have been approved for use in haematological malignancies. Here we provide a background to the biology of chromatin modifications and review some of the evidence validating histone deacetylases and DNA methyltransferases as targets for anti-cancer drug discovery. We then focus on two of the key issues in this field; the identification of novel inhibitors to overcome shortcomings of first generation agents and the potential role of histone deacetylase and DNA methyltransferase inhibitors in combination therapies for oncology. Finally, we highlight some of the challenges that will need to addressed to further progress the development of epigenetic-based therapies for cancer.
Keywords: Epigenetic, chromatin, histone, DNA methylation, acetylation, histone deacetylase, inhibitor
Current Cancer Drug Targets
Title: Epigenetic Therapy: Histone Acetylation, DNA Methylation and Anti-Cancer Drug Discovery
Volume: 9 Issue: 8
Author(s): A. Ganesan, L. Nolan, S. J. Crabb and G. Packham
Affiliation:
Keywords: Epigenetic, chromatin, histone, DNA methylation, acetylation, histone deacetylase, inhibitor
Abstract: Histone proteins are subject to a diverse range of post-translational modifications which, along with DNA methylation, play a major role in controlling gene expression, cell division, survival and differentiation. Alterations in these chromatin modifications are thought to contribute to important human diseases including cancer. Inhibition of the enzymes that introduce and remove these chromatin modifications is proving an effective approach to cancer therapy and inhibitors of histone deacetylases and DNA methyltransferases have been approved for use in haematological malignancies. Here we provide a background to the biology of chromatin modifications and review some of the evidence validating histone deacetylases and DNA methyltransferases as targets for anti-cancer drug discovery. We then focus on two of the key issues in this field; the identification of novel inhibitors to overcome shortcomings of first generation agents and the potential role of histone deacetylase and DNA methyltransferase inhibitors in combination therapies for oncology. Finally, we highlight some of the challenges that will need to addressed to further progress the development of epigenetic-based therapies for cancer.
Export Options
About this article
Cite this article as:
Ganesan A., Nolan L., Crabb J. S. and Packham G., Epigenetic Therapy: Histone Acetylation, DNA Methylation and Anti-Cancer Drug Discovery, Current Cancer Drug Targets 2009; 9 (8) . https://dx.doi.org/10.2174/156800909790192428
DOI https://dx.doi.org/10.2174/156800909790192428 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member:
Recent Patents on Anti-Cancer Drug Discovery Circulating Levels of Angiogenic Cytokines in Waldenstrom’s Macroglobulinemia: Clinical Correlations
Current Angiogenesis (Discontinued) Editorial [Hot Topic: Recent Advances Into the Molecular Mechanisms and Therapeutic Targeting of Hepatocellular Carcinoma (Guest Editors: Dr. Mei-Sze Chua and Li Wang)]
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Metabolic Profiling and Imaging of Prostate Cancer
Current Metabolomics Role of Inflammation-Associated Microenvironment in Tumorigenesis and Metastasis
Current Cancer Drug Targets The Functions of Histone Modification Enzymes in Cancer
Current Protein & Peptide Science Diagnosis and Treatment of Unilateral Forms of Primary Aldosteronism
Current Hypertension Reviews Regulation of Mesenchymal Phenotype by MicroRNAs in Cancer
Current Cancer Drug Targets Polymeric Micelles for Ocular Delivery: Progress and Issues
Pharmaceutical Nanotechnology Epigenome-Wide Association Studies (EWAS) in Cancer
Current Genomics Deubiquitinating Enzymes as Promising Drug Targets for Infectious Diseases
Current Pharmaceutical Design Integrin Function and Signaling as Pharmacological Targets in Cardiovascular Diseases and in Cancer
Current Pharmaceutical Design HIV Entry Inhibitors Targeting gp41: From Polypeptides to Small-Molecule Compounds
Current Pharmaceutical Design Recent Advances in Gene Therapy of Endometriosis
Recent Patents on DNA & Gene Sequences New Agents – Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing
Current Cancer Therapy Reviews Evaluating Gene Delivery Using N-triethyl Chitosan Nanoparticles to AsPC-1 Cells and Predicting the Relation between Transfection, Cytotoxicity and Charge Ratio of Nanoparticles Via Mathematical Models
Drug Delivery Letters Editorial [Hot Topic: The Medicinal Chemistry of Agents Targeting the Nuclear Hormone Receptor Guest Editor: John Regan ]
Current Topics in Medicinal Chemistry Role of Cathepsin K in Normal Joints and in the Development of Arthritis
Current Drug Targets Molecular Pathogenesis of Philadelphia-Positive Chronic Myeloid Leukemia – is it all BCR-ABL?
Current Cancer Drug Targets Anticancer Actions of Omega-3 Fatty Acids - Current State and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry